Search results for "Toxic"

showing 10 items of 6968 documents

Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.

2018

γδ T cells represent less than 5% of circulating T cells; they exert a potent cytotoxic function against tumor or infected cells and secrete cytokines like conventional αβ T cells. As αβ T cells γδ T cells reside in the typical T cell compartments (the lymph nodes and spleen), but are more widely distributed in tissues throughout the body. For these reasons, some investigators are exploring the possibility of immunotherapies aimed to expand and activate Vδ2 T cells, or using them as Chimeric Antigen Receptor carriers. However, the role of immunosuppressive microenvironment on Vδ2 T cells during infections and cancers has not been completely elucidated. In particular, the effects of myeloid-…

0301 basic medicinelcsh:Immunologic diseases. AllergyCytotoxicity Immunologicγmedicine.medical_treatmentT cellδImmunologyAntitumoral activityT cellsSpleenLymphocyte ActivationJurkat cellsγδ T cellsImmunophenotyping03 medical and health sciencesInterferon-gamma0302 clinical medicineT-Lymphocyte SubsetsCell Line TumorNeoplasmsmedicineMyeloid-derived suppressor cellImmunology and AllergyCytotoxic T cellHumansIFN-γantitumoral activityArginaseChemistryMyeloid-Derived Suppressor CellsDegranulationReceptors Antigen T-Cell gamma-deltaImmunotherapy030104 developmental biologymedicine.anatomical_structureCell cultureCancer researchMyeloid-derived Suppressor CellLeukocytes MononuclearCytokinesImmunotherapyimmunotherapylcsh:RC581-607Biomarkers030215 immunologyFrontiers in immunology
researchProduct

Characterization of zolbetuximab in pancreatic cancer models

2018

ABSTRACT In healthy tissue, the tight junction protein Claudin 18.2 (CLDN18.2) is present only in the gastric mucosa. Upon malignant transformation of gastric epithelial tissue, perturbations in cell polarity lead to cell surface exposure of CLDN18.2 epitopes. Moreover, CLDN18.2 is aberrantly expressed in malignancies of several other organs, such as pancreatic cancer (PC). A monoclonal antibody, zolbetuximab (formerly known as IMAB362), has been generated against CLDN18.2. In a phase 2 clinical trial (FAST: NCT01630083), zolbetuximab in conjunction with chemotherapy prolonged overall and progression-free survival over chemotherapy alone and improved quality of life. In this study, the mech…

0301 basic medicinelcsh:Immunologic diseases. AllergyImmunologyCellclaudin 18.2pancreatic cancerlcsh:RC254-282Malignant transformation03 medical and health sciences0302 clinical medicinePancreatic cancermedicineImmunology and AllergyCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchAntibody-dependent cell-mediated cytotoxicityChemistryimab362medicine.diseasetargeted therapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensComplement-dependent cytotoxicity030104 developmental biologymedicine.anatomical_structureOncologyadccCell culturemonoclonal antibody030220 oncology & carcinogenesisCancer researchimmunotherapyzolbetuximablcsh:RC581-607Ex vivoantibody-dependent cellular cytotoxicityOncoImmunology
researchProduct

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells

2018

CD38 is overexpressed by multiple myeloma cells and has emerged as a target for therapeutic antibodies. Nanobodies are soluble single domain antibody fragments derived from the VHH variable domain of heavy chain antibodies naturally occurring in camelids. We previously identified distinct llama nanobodies that recognize three non-overlapping epitopes of the extracellular domain of CD38. Here, we fused these VHH domains to the hinge, CH2, and CH3 domains of human IgG1, yielding highly soluble chimeric llama/human heavy chain antibodies (hcAbs). We analyzed the capacity of these hcAbs to mediate complement-dependent cytotoxicity (CDC) to CD38-expressing human multiple myeloma and Burkitt lymp…

0301 basic medicinelcsh:Immunologic diseases. AllergyRecombinant Fusion ProteinsImmunologyAntineoplastic AgentsEpitope03 medical and health sciencesbiparatopic antibodiesAntigens Neoplasmhemic and lymphatic diseasesCell Line TumorAntibodies BispecificImmunology and AllergyAnimalsHumansCytotoxicitycomplement-dependent cytotoxicityOriginal ResearchHeavy-chain antibodybiologyheavy chain antibodyantibody engineeringChemistryAntibody-Dependent Cell CytotoxicityDaratumumabAntibodies MonoclonalComplement System ProteinsSingle-Domain AntibodiesADP-ribosyl Cyclase 1Complement-dependent cytotoxicityCell biologymultiple myelomananobody030104 developmental biologySingle-domain antibodyCell culturebiology.proteinEpitopes B-LymphocyteImmunotherapyAntibodylcsh:RC581-607Immunoglobulin Heavy ChainsCamelids New WorldCD38Frontiers in Immunology
researchProduct

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

2019

ABSTRACT HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8+ T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with ac…

0301 basic medicinelcsh:Immunologic diseases. AllergyT cellImmunologyhpv16-positive malignancieslcsh:RC254-282t cell memoryhpv 16 rna-lpx03 medical and health sciences0302 clinical medicineImmune systemAntigenImmunology and AllergyCytotoxic T cellMedicineOriginal Researchbusiness.industryCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologymedicine.anatomical_structureOncologyImmunization030220 oncology & carcinogenesisCancer researchCancer vaccinebusinesscancer vaccinelcsh:RC581-607CD8e7OncoImmunology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

2019

TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. Here we present the preclinical characterization of SC1, a novel synthetic agonist with exquisite specificity for TLR7. We found that intravenously administered SC1 mediates systemic release of type I interferon, but not of proinflammatory cytokines such as TNFα and IL6, and results in activation of circulating immune cells. Tumors of SC1-treated mice have brisk immune cell infiltrates and are polarized towards a Th1 type signature. Intratumoral CD8(+) T cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsImmunologytype i interferonlcsh:RC254-282Proinflammatory cytokinetlr7 ligand03 medical and health sciences0302 clinical medicineImmune systemInterferonmedicineImmunology and AllergyCytotoxic T cellOriginal ResearchToll-like receptorcancer immunotherapybusiness.industryTLR7Acquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchbusinesslcsh:RC581-607CD8medicine.drugOncoImmunology
researchProduct

A non-functional neoepitope specific CD8+ T-cell response induced by tumor derived antigen exposure in vivo

2018

Cancer-associated mutations, mostly single nucleotide variations, can act as neoepitopes and prime targets for effective anti-cancer T-cell immunity. T cells recognizing cancer mutations are critical for the clinical activity of immune checkpoint blockade (ICB) and they are potent vaccine antigens. High frequencies of mutation-specific T cells are rarely spontaneously induced. Hence, therapies that broaden the tumor specific T-cell response are of interest. Here, we analyzed neoepitope-specific CD8+ T-cell responses mounted either spontaneously or after immunotherapy regimens, which induce local tumor inflammation and cell death, in mice bearing tumors of the widely used colon carcinoma cel…

0301 basic medicinelcsh:Immunologic diseases. Allergycd8+ t cellsmedicine.medical_treatmentImmunologyBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyAntigenmedicineImmunology and AllergyCytotoxic T cellneoepitopescancer immunotherapycd8+ t cell cytotoxicityT-cell receptorImmunotherapyTumor-Derivedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensImmune checkpointt cell priming030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchlcsh:RC581-607CD8OncoImmunology
researchProduct

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

2017

γδ T cells usually infiltrate many different types of cancer, but it is unclear whether they inhibit or promote tumor progression. Moreover, properties of tumor-infiltrating γδ T cells and those in the corresponding normal tissue remain largely unknown. Here we have studied features of γδ T cells in colorectal cancer, normal colon tissue and peripheral blood, and correlated their levels with clinicopathologic hallmarks. Flow cytometry and transcriptome analyses showed that the tumor comprised a highly variable rate of TILs (5–90%) and 4% γδ T cells on average, with the majority expressing Vδ1. Most Vδ1 and Vδ2 T cells showed a predominant effector memory phenotype and had reduced production…

0301 basic medicinelcsh:Immunologic diseases. Allergycolon cancer; DFS; IFN-g; TILs; gd T cells; Immunology and Allergy; Immunology; OncologyColorectal cancerImmunologyBiologyifn-γDFStilslcsh:RC254-28203 medical and health sciencesIFN-gmedicineCytotoxic T cellImmunology and AllergyOriginal ResearchSettore MED/04 - Patologia Generaleγδ t cellsCancergd T cellTILmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologycolon cancerOncologyTumor progressionImmunologylcsh:RC581-607Oncoimmunology
researchProduct

Anticancer properties of 5Z-(4- fuorobenzylidene)-2-(4- hydroxyphenylamino)-thiazol-4-one

2019

Abstract4-thiazolidinones, which are privileged structures in medicinal chemistry, comprise the well-known class of heterocycles and are a source of new drug-like compounds. Undoubtedly, the 5-bulky-substituted-2,4-thiazolidinediones - a class of antihyperglycemic glitazones, which are peroxisome proliferator-activated receptor gamma (PPARγ) agonists, are the most described group among them. As there are various chemically distinct 4-thiazolidinones, different subtypes have been selected for studies; however, their main pharmacological profiles are similar. The aim of this study was to evaluate the anticancer activity of 5Z-(4-fluorobenzylidene)-2-(4-hydroxyphenylamino)-thiazol-4-one (Les-2…

0301 basic medicinelcsh:MedicineAntineoplastic AgentsApoptosisDrug developmentArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCell Line TumorLactate dehydrogenaseHumansViability assaylcsh:ScienceCytotoxicityReceptorchemistry.chemical_classificationReactive oxygen speciesMultidisciplinaryDose-Response Relationship DrugL-Lactate DehydrogenaseMolecular medicineCaspase 3lcsh:RMetabolismPeroxisomeThiazoles030104 developmental biologychemistryBiochemistryA549 CellsPreclinical researchCell culturelcsh:QCaco-2 CellsReactive Oxygen Species030217 neurology & neurosurgeryScientific Reports
researchProduct

The shell of the invasive bivalve species Dreissena polymorpha: biochemical, elemental and textural Investigations.

2016

28 pages; International audience; The zebra mussel Dreissena polymorpha is a well-established invasive model organism. Although extensively used in environmental sciences, virtually nothing is known of the molecular process of its shell calcification. By describing the microstructure, geochemistry and biochemistry/proteomics of the shell, the present study aims at promoting this species as a model organism in biomineralization studies, in order to establish a bridge with ecotoxicology, while sketching evolutionary conclusions. The shell of D. polymorpha exhibits the classical crossed-lamellar/complex crossed lamellar combination found in several heterodont bivalves, in addition to an extern…

0301 basic medicinelcsh:MedicineInvasive Species010501 environmental sciencesProteomicsEcotoxicology01 natural sciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics MethodsMaterials PhysicsLectinsMusselslcsh:ScienceMicrostructureGel ElectrophoresisStainingMineralsMultidisciplinarybiologyOrganic CompoundsPhysicsMonosaccharidesBiological EvolutionEuropeChemistry[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Physical SciencesFranceSequence AnalysisResearch ArticleSilver StainingBivalvesMaterials ScienceShell (structure)CarbohydratesSequence DatabasesElectrophoretic StainingResearch and Analysis MethodsDreissenaDreissenaCoomassie Blue staining03 medical and health sciencesElectrophoretic TechniquesSpecies ColonizationAnimal Shells[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Botany[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyEcotoxicologyAnimals[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular Biology14. Life underwaterShell calcificationMolecular Biology TechniquesSequencing Techniques[SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/BiomaterialsMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology0105 earth and related environmental scienceslcsh:ROrganic ChemistryEcology and Environmental SciencesOrganismsChemical CompoundsBiology and Life SciencesProteinsMolluscs[ SDV.IB.BIO ] Life Sciences [q-bio]/Bioengineering/Biomaterialsbiology.organism_classificationInvertebrates030104 developmental biologyCalcium carbonateBiological DatabaseschemistrySpecimen Preparation and TreatmentZebra mussellcsh:QIntroduced SpeciesBiomineralization
researchProduct